Trofinetide · LAVENDER

A finished trial with results published in 2023.

Study level

The aim, simply

LAVENDER compared trofinetide with placebo over 12 weeks in 187 participants. The linked paper reports effects and tolerability.

Criteria: guidance, not eligibility

The studied population was girls and women aged 5–20. This study no longer recruits.

What this cannot tell us

A study record describes research, not a guaranteed benefit or treatment access in your country.

Only the trial team can confirm eligibility. Age and country are not enough: the protocol includes other criteria. Status may also vary by study site.

Centre level

Partial list. A registry listing does not confirm a place. Check directly with the site.

Sites not transcribed in this selection. Consult the official record.